TY - JOUR
T1 - Malignant germ cell tumors (gcts) in the us
T2 - a 27-year perspective
AU - Smith, Harriet
AU - Laming, Letitia B.
AU - Quails, Clifford R.
AU - Padilla, Luis A.
AU - Verschracgcn, Claire E.
PY - 1996
Y1 - 1996
N2 - Objective: To evaluate population-based trends in incidence and survival for women with malignant GCTs (1973-1999). Methods: The SEER database was used to calculate overall and 5-year incidence rates (AAIRs) and survival by age at diagnosis, race, stage, and histology. Frequency distributions were compared using Fishers exact tests, and trends using the Jonckheere-Terpstra lest. Results: A total of 1,119 cases were identified, 1098 (98.1%) ovarian in origin. The overall AAIR was 0.36/100,000 woman-years. By histology, 373 (33.3%) were dysgerminomas, 461 (41.2%) were teratomas (433 immature, 28 mature with malignant degeneration), and 285 (25.5%) were non-dysgerminomas (157 endodermal sinus, 51 embryonal carcinoma, 24 choriocarcinoma, 53 mixed). For dysterminomas, but not other cell types, the AAIRs significantly decreased over calendar time (P = 0.02). By race (white, black, others), others had higher AAIRs (0.32, 0.35, 0.41, P = 0.009). By race, whites and others had higher rates of dysgerminoma compared with blacks (P = 0.01). For localized and distant disease, AAIRs rates decreased by 33.9%, and 23.4%, respectively, but increased for regional disease by 154%, (3.71% /year, P = 0.001). The 5-year relative survival was 82.6%. Survival varied significantly by histology (dysgerminomas 93.2%, teratomas 83.4%, other non-dysgerminomas 68.1%), stage (localized 93.3%, regional 83.7%, distant 66.2%, unstaged 70.0%), and age (0-9 yrs 97.4% vs. 60+ yrs, 22.2%, P < 0.001), but not by race (whites 89.3%, blacks 77.7%, others 82.3%, P = 0.70). Over 27 years, the 5-year survival rates increased by 33%. Conclusions: Malignant GCT AAIRs have decreased for dysgerminomas, and for distant and unstaged disease, and overall survival has also dramatically improved (by 33%). Dysgerminomas have significantly higher survival rates compared to other cell types. Unlike epithelial ovarian cancers, these data indicate that advances in treatment strategies have significantly impacted outcome.
AB - Objective: To evaluate population-based trends in incidence and survival for women with malignant GCTs (1973-1999). Methods: The SEER database was used to calculate overall and 5-year incidence rates (AAIRs) and survival by age at diagnosis, race, stage, and histology. Frequency distributions were compared using Fishers exact tests, and trends using the Jonckheere-Terpstra lest. Results: A total of 1,119 cases were identified, 1098 (98.1%) ovarian in origin. The overall AAIR was 0.36/100,000 woman-years. By histology, 373 (33.3%) were dysgerminomas, 461 (41.2%) were teratomas (433 immature, 28 mature with malignant degeneration), and 285 (25.5%) were non-dysgerminomas (157 endodermal sinus, 51 embryonal carcinoma, 24 choriocarcinoma, 53 mixed). For dysterminomas, but not other cell types, the AAIRs significantly decreased over calendar time (P = 0.02). By race (white, black, others), others had higher AAIRs (0.32, 0.35, 0.41, P = 0.009). By race, whites and others had higher rates of dysgerminoma compared with blacks (P = 0.01). For localized and distant disease, AAIRs rates decreased by 33.9%, and 23.4%, respectively, but increased for regional disease by 154%, (3.71% /year, P = 0.001). The 5-year relative survival was 82.6%. Survival varied significantly by histology (dysgerminomas 93.2%, teratomas 83.4%, other non-dysgerminomas 68.1%), stage (localized 93.3%, regional 83.7%, distant 66.2%, unstaged 70.0%), and age (0-9 yrs 97.4% vs. 60+ yrs, 22.2%, P < 0.001), but not by race (whites 89.3%, blacks 77.7%, others 82.3%, P = 0.70). Over 27 years, the 5-year survival rates increased by 33%. Conclusions: Malignant GCT AAIRs have decreased for dysgerminomas, and for distant and unstaged disease, and overall survival has also dramatically improved (by 33%). Dysgerminomas have significantly higher survival rates compared to other cell types. Unlike epithelial ovarian cancers, these data indicate that advances in treatment strategies have significantly impacted outcome.
UR - http://www.scopus.com/inward/record.url?scp=33749567163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749567163&partnerID=8YFLogxK
U2 - 10.1097/00130404-200311000-00097
DO - 10.1097/00130404-200311000-00097
M3 - Article
AN - SCOPUS:33749567163
SN - 1528-9117
VL - 9
SP - 511
EP - 512
JO - Cancer Journal
JF - Cancer Journal
IS - 6
ER -
